ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1017

Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis

Xuan Zhang1 and Xunyao Wu2, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital, beijing, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Apoptosis, complement, cytokines and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A delayed diagnoses and therapy of ACPA (Anti cyclic citrullinated peptide antibody)-negative RA patients might be associated with effective serum biomarkers in clinic.

Methods: In the present study, we performed protein chip analysis in 30 HC, 60 patients with RA (including 30 ACPA-positive and 30 ACPA-negative), and 30 with other Autoimmune diseases.

Results: We found that anti-pentraxin 3 autoantibodies were significantly up-regulated in both APCA negative and positive RA patients compared with healthy controls and other AIDs with high sensitivity and specificity. Enlarged samples of small protein chip confirmed the up-regulated anti-PTX3 level in APCA negative RA patients. Further ELISA analysis of anti-PTX3 and its autoantigen pentraxin 3 in serum and synovial fluid showed that both anti-PTX3 and PTX3 was significantly up-regulated in ACPA positive and negative RA patients and positively correlated with clinical manifestations of DAS28 and RF as well as serum inflammatory cytokines, IL-1β, IL-6 and TNF-α. We also showed that increased PTX3 secretion was derived from CD19+ B cells and preferentially bound to CD14+ monocytes in a C1q-dependent manner. Serum C1q level was higher in RA patients compared with HC and AIDs and positively correlated with PTX3 expression in RA patients. Moreover, PTX3 treatment of CD14+ monocytes combined with C1q in vitro could significantly up-regulated the activation marker CD40 expression and increased 7-AAD+Annexin V+ double positive late apoptotic cells in some RA patients. The induction of CD14+ monocytes apoptosis strongly inhibited RA-related inflammatory cytokine IL-1β, IL-6 and TNF-α secretion after LPS stimulation in vitro. LDH releasement and the cleaved GSDMD and capase-1 was significantly down-regulated while cleaved caspase-3 and Bcl-2 was significantly up-regulated after C1q and PTX3 combined treatment.

Conclusion: Our results demonstrated a detection of Anti-Pentraxin-3 autoantidies in ACPA-negative RA Patients and autoantigen PTX3 combined with C1q could effectively inhibit GSDMD mediated pyroptosis and inflammatory cytokine releasement.


Disclosure: X. Zhang, None; X. Wu, None.

To cite this abstract in AMA style:

Zhang X, Wu X. Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/autoantigen-pentraxin-3-is-an-inflammatory-cytokine-storms-suppressor-by-switching-monocytes-pyroptosis-to-apoptosis-in-a-complement-dependent-manner-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantigen-pentraxin-3-is-an-inflammatory-cytokine-storms-suppressor-by-switching-monocytes-pyroptosis-to-apoptosis-in-a-complement-dependent-manner-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology